At the 33.8-month median follow-up

Progression free survival (PFS) Opdualag vs nivolumab¹

Descriptive analysis. PFS was defined as the time between the date of randomization and the earliest date of documented disease progression, or death from any cause. Statistical model for HR: stratified Cox proportional hazards model. Stratified by LAG-3, BRAF mutation status, and AJCC M stage. PD-L1 was removed from stratification because it led to subgrounds with < 10 patients.

CI = confidence interval; HR = hazard ratio;

Reference: 

1. Data on file. BMS-REF-NIVO+RELA-0014. Princeton, NJ: Bristol-Myers Squibb Company; 2023.